Deferasirox demonstrates a dose-dependent reduction in liver iron concentration and consistent efficacy across subgroups of non-transfusion-dependent thalassemia patients

Documenti analoghi

• Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study
  di: Taher, Ali T., et al.
  Pubblicazione: (2013)
• Approaching low liver iron burden in chelated patients with non-transfusion-dependent thalassemia: the safety profile of deferasirox
  di: Taher, Ali T, et al.
  Pubblicazione: (2014)
• Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes
  di: Taher, Ali T, et al.
  Pubblicazione: (2016)
• Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload
  di: Taher, Ali, et al.
  Pubblicazione: (2009)
• Effects of deferasirox-deferoxamine on myocardial and liver iron in patients with severe transfusional iron overload
  di: Aydinok, Yesim, et al.
  Pubblicazione: (2015)